CytomX Therapeutics Inc
Company Profile
Business description
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Contact
151 Oyster Point Boulevard
Suite 400
South San FranciscoCA94080
USAT: +1 650 515-3185
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
121
Stocks News & Analysis
stocks
Paying more for new customers is a troubling sign for ASX share
stocks
10 US stocks with the largest fair value estimate increases during Q4 earnings
stocks
Berkshire Hathaway earnings: Cash hits record $373 billion on mostly solid results across the firm
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,117.10 | 40.60 | -0.44% |
| CAC 40 | 8,201.83 | 97.99 | 1.21% |
| DAX 40 | 24,201.79 | 411.14 | 1.73% |
| Dow JONES (US) | 48,561.44 | 343.34 | -0.70% |
| FTSE 100 | 10,572.76 | 88.63 | 0.85% |
| HKSE | 25,249.48 | 518.60 | -2.01% |
| NASDAQ | 22,516.69 | 232.17 | -1.02% |
| Nikkei 225 | 54,245.54 | 2,033.51 | -3.61% |
| NZX 50 Index | 13,531.12 | 125.53 | -0.92% |
| S&P 500 | 6,827.79 | 11.16 | 0.16% |
| S&P/ASX 200 | 8,901.20 | 35.80 | -0.40% |
| SSE Composite Index | 4,082.47 | 40.20 | -0.98% |